Business
Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100
Oakville, Ontario--(Newsfile Corp. - October 1, 2019) - Cardiol Therapeutics Inc. ( TSX: CRDL)...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100Oakville, Ontario--(Newsfile Corp. - October 1, 2019) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (\"Cardiol\" or the \"Company\"), a leader in the production of pharmaceutical CBD products and in the development of innovative CBD medicines for heart disease, announces that it has completed the manufacturing scale-up for commercialization of its CardiolRx™100 CBD formulation. CardiolRx 100 (100 mg/mL CBD with 3,000 mg of CBD per bottle) is designed to be the safest and most consistent high concentration CBD formulation available to Canadians that is THC free (<10ppm). It is pharmaceutically produced in a Health Canada approved, FDA registered, and cGMP facility. Cardiol is also developing additional CBD products for medical use that may be suitable options when a lesser strength CBD is necessary, including formulations that contain 50 mg/mL and 25 mg/mL CBD.\"We are dedicated to producing THC free CBD products for medical use that meet the highest standards for purity, consistency, and manufacturing,\" said David Elsley, President and CEO of Cardiol Therapeutics. \"Completion of the manufacturing scale-up of our CardiolRx 100 product is an important milestone supporting this objective and serves to establish our path to commercial introduction.\" Cardiol plans to commercialize CardiolRx 100 in the $1.2 billion-dollar market for medicinal cannabinoids in Canada during Q4 2019 and is pursuing market introduction opportunities in Europe and Latin America. CardiolRx 100 will initially be made available to Canadians for medical use in compliance with the Cannabis Regulations. High concentration CBD has been approved for use in certain types of epilepsy in both the U.S. and Europe and has been prescribed by physicians in Canada for use in conditions such as epilepsy, pain management, anxiety and depression. Chronic pain affects the quality of life of one in five Canadians and is the most common reason individuals seek healthcare. In addition, approximately 3.5 million Canadians annually access healthcare for mood or anxiety disorders, conditions that are generally poorly treated.Based on the large body of experimental evidence of the powerful anti-inflammatory activity of CBD in models of cardiovascular dis...